Cardiogenic shock (CS) remains the most common cause of death in patients admitted with
acute myocardial infarction (AMI) and mortality remained nearly unchanged in the range of …

Background Intra‐aortic balloon pump counterpulsation (IABP) is currently the most
commonly used mechanical assist device for patients with cardiogenic shock due to acute …

Background. Atherothrombotic disease, including coronary artery disease (CAD) and
peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial …

Background In current international guidelines, intraaortic balloon counterpulsation is
considered to be a class I treatment for cardiogenic shock complicating acute myocardial …

The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of
cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but …

Aims Patient access to reperfusion therapy and the use of primary percutaneous coronary
intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries …

Background In patients who have acute myocardial infarction with cardiogenic shock, early
revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) …

Background Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the
standard of care after percutaneous coronary intervention (PCI) for patients with atrial …

Background Extracorporeal life support (ECLS) is increasingly used in the treatment of
infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality …

Background Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest.
However, the benefits of early coronary angiography and revascularization in resuscitated …